Specifically regulated genes in malignant melanoma tissues identified by subtractive hybridization

بواسطة Hipfel, R, Schittek, B, Bodingbauer, Y, Garbe, C
منشور في 2000

Expression of interleukin 10 in human melanoma.

بواسطة Krüger-Krasagakes, S., Krasagakis, K., Garbe, C., Schmitt, E., Hüls, C., Blankenstein, T., Diamantstein, T.
منشور في 1994

The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients.

بواسطة Häffner, A. C., Garbe, C., Burg, G., Büttner, P., Orfanos, C. E., Rassner, G.
منشور في 1992

Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma

بواسطة Bauer, J, Kilic, E, Vaarwater, J, Bastian, B C, Garbe, C, de Klein, A
منشور في 2009

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study

بواسطة Forschner A, Weißgraeber S, Hadaschik D, Schulze M, Kopp M, Kelkenberg S, Sinnberg T, Garbe C, Biskup S, Battke F
منشور في 2020-06-01

Determinants of survival in patients with brain metastases from cutaneous melanoma

بواسطة Staudt, M, Lasithiotakis, K, Leiter, U, Meier, F, Eigentler, T, Bamberg, M, Tatagiba, M, Brossart, P, Garbe, C
منشور في 2010

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

بواسطة Radny, P, Caroli, U M, Bauer, J, Paul, T, Schlegel, C, Eigentler, T K, Weide, B, Schwarz, M, Garbe, C
منشور في 2003

Naturally Processed Dermcidin-Derived Peptides Do Not Permeabilize Bacterial Membranes and Kill Microorganisms Irrespective of Their Charge

بواسطة Steffen, H., Rieg, S., Wiedemann, I., Kalbacher, H., Deeg, M., Sahl, H.-G., Peschel, A., Götz, F., Garbe, C., Schittek, B.
منشور في 2006

Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis

بواسطة Weide, B, Elsässer, M, Büttner, P, Pflugfelder, A, Leiter, U, Eigentler, T K, Bauer, J, Witte, M, Meier, F, Garbe, C
منشور في 2012

Microarchitecture Is Severely Compromised but Motor Protein Function Is Preserved in Dystrophic mdx Skeletal Muscle

بواسطة Friedrich, O., Both, M., Weber, C., Schürmann, S., Teichmann, M.D.H., von Wegner, F., Fink, R.H.A., Vogel, M., Chamberlain, J.S., Garbe, C.
منشور في 2010

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

بواسطة Long, G V, Tykodi, S S, Schneider, J G, Garbe, C, Gravis, G, Rashford, M, Agrawal, S, Grigoryeva, E, Bello, A, Roy, A, Rollin, L, Zhao, X
الحاوية / القاعدة Ann Oncol (2018)

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

بواسطة Hauschild, A, Garbe, C, Stolz, W, Ellwanger, U, Seiter, S, Dummer, R, Ugurel, S, Sebastian, G, Nashan, D, Linse, R, Achtelik, W, Mohr, P, Kaufmann, R, Fey, M, Ulrich, J, Tilgen, W
منشور في 2001

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

بواسطة Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., Robert, C.
الحاوية / القاعدة Ann Oncol (2014)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

بواسطة Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
الحاوية / القاعدة Ann Oncol (2017)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

بواسطة Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
الحاوية / القاعدة Ann Oncol (2019)